scispace - formally typeset
Search or ask a question
Journal ArticleDOI

Laser, LED (photothérapie) et radiofréquence du vagin pour le traitement de l’atrophie vaginale, de l’incontinence urinaire, du prolapsus et de la béance vaginale : que dit la littérature ?

01 Jun 2021-Progrès en Urologie - FMC (Elsevier Masson)-Vol. 31, Iss: 2
TL;DR: Ces nouvelles energies appliquees a la pelvi-perineologie pourraient permettre de prendre en charge de facon non invasive certaines patientes souffrant de diverses pathologies.
About: This article is published in Progrès en Urologie - FMC.The article was published on 2021-06-01. It has received None citations till now.
References
More filters
Journal ArticleDOI
TL;DR: CO2 vaginal laser alone or in combination with topical estriol is a good treatment option for VVA symptoms and sexual-related pain with vaginal laser treatment might be of concern.
Abstract: Objective:The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA).Methods:A total of 45

153 citations

Journal ArticleDOI
TL;DR: At 6 months, fractionated CO2 vaginal laser and vaginal estrogen treatment resulted in similar improvement in genitourinary syndrome of menopause symptoms as well as urinary and sexual function.
Abstract: Objective The aim of the study was to compare 6-month efficacy and safety for treatment of vaginal dryness/genitourinary syndrome of menopause in women undergoing fractionated CO2 vaginal laser therapy to women using estrogen vaginal cream. Methods This multicenter, randomized trial compared fractionated CO2 laser to estrogen cream at 6 institutions. We included menopausal women with significant vaginal atrophy symptoms and we excluded women with prolapse below stage 2, recent pelvic surgery, prior mesh surgery, active genital infection, history of estrogen sensitive malignancy, and other autoimmune conditions. The primary outcome was the visual analog scale vaginal dryness score. Secondary outcomes included evaluation of vaginal atrophy, quality of life symptoms, assessment of sexual function, and urinary symptoms. Adverse events (AEs) and patient global impression of improvement (PGI-I) and satisfaction were also assessed. Results Sixty-nine women were enrolled in this trial before enrollment was closed due to the Federal Drug Administration requiring the sponsor to obtain and maintain an Investigational Device Exemption. Of the 69 participants enrolled, 62 completed the 6-month protocol; 30 women were randomized to the laser and 32 to estrogen cream from June 2016 to September 2017. Demographics did not differ between groups except the laser group was less parous (0 [range 0-4] vs 2 [0-6], P = 0.04). On patient global impression, 85.8% of laser participants rated their improvement as "better or much better" and 78.5% reported being either "satisfied or very satisfied" compared to 70% and 73.3% in the estrogen group; this was not statistically different between groups. On linear regression, mean difference in female sexual function index scores was no longer statistically significant; and, vaginal maturation index scores remained higher in the estrogen group (adj P value 0.02); although, baseline and 6-month follow-up vaginal maturation index data were only available for 34 participants (16 laser, 18 estrogen). Conclusions At 6 months, fractionated CO2 vaginal laser and vaginal estrogen treatment resulted in similar improvement in genitourinary syndrome of menopause symptoms as well as urinary and sexual function. Overall, 70% to 80% of participants were satisfied or very satisfied with either treatment and there were no serious adverse events. : Video Summary:http://links.lww.com/MENO/A470.

86 citations

Journal ArticleDOI
TL;DR: The non-ablative Er:YAG laser therapy improves the impact of SUI symptoms on quality of life and sexual function in premenopausal parous women significantly better than placebo and provides a promising minimally-invasive safe treatment alternative for SUI.

82 citations

Journal ArticleDOI
TL;DR: A single treatment of RFc therapy was found to be safe and associated with both improved vaginal laxity and improved sexual function, and the results from this trial support the use of a novel non-surgical therapy for vagina laxity.

76 citations

Journal ArticleDOI
TL;DR: The use of fractional CO2 laser therapy to treat genitourinary syndrome resulted in better short-term effects than those of promestriene or lubricant with respect to improving the vaginal health in postmenopausal women.
Abstract: Objective:The aim of this study was to compare the effects of fractional CO2 laser therapy, promestriene, and vaginal lubricants on genitourinary syndrome treatment and sexual function in postmenopausal women.Methods:We performed a randomized clinical trial including 72 postmenopausal women

54 citations